Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Article
|
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilitiesCancer discovery, 2015-08, Vol.5 (8), p.860-8772015 American Association for Cancer Research. ;ISSN: 2159-8274 ;EISSN: 2159-8290 ;DOI: 10.1158/2159-8290.CD-14-1236 ;PMID: 26069186Full text available |
|
2 |
Material Type: Article
|
Adjuvant chemotherapy for resected early‐stage non‐small cell lung cancerCochrane database of systematic reviews, 2015-03, Vol.2015 (3), p.CD011430-CD011430 [Peer Reviewed Journal]Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. ;ISSN: 1469-493X ;EISSN: 1465-1858 ;EISSN: 1469-493X ;DOI: 10.1002/14651858.CD011430 ;PMID: 25730344Full text available |
|
3 |
Material Type: Article
|
Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trialThorax, 2017-09, Vol.72 (9), p.825-831 [Peer Reviewed Journal]Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/. ;Copyright: 2017 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing ;ISSN: 0040-6376 ;EISSN: 1468-3296 ;DOI: 10.1136/thoraxjnl-2016-209825 ;PMID: 28377492Full text available |
|
4 |
Material Type: Article
|
First-Line Immunotherapy for Non-Small-Cell Lung CancerJournal of clinical oncology, 2022-02, Vol.40 (6), p.586-597 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.21.01497 ;PMID: 34985920Full text available |
|
5 |
Material Type: Article
|
Lung cancer: current therapies and new targeted treatmentsThe Lancet (British edition), 2017-01, Vol.389 (10066), p.299-311 [Peer Reviewed Journal]Elsevier Ltd ;2017 Elsevier Ltd ;Copyright © 2017 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Jan 21, 2017 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(16)30958-8 ;PMID: 27574741 ;CODEN: LANCAOFull text available |
|
6 |
Material Type: Article
|
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and TreatmentMayo Clinic proceedings, 2019-08, Vol.94 (8), p.1623-1640 [Peer Reviewed Journal]2019 Mayo Foundation for Medical Education and Research ;Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved. ;COPYRIGHT 2019 Elsevier, Inc. ;ISSN: 0025-6196 ;EISSN: 1942-5546 ;DOI: 10.1016/j.mayocp.2019.01.013 ;PMID: 31378236Full text available |
|
7 |
Material Type: Article
|
The biology and management of non-small cell lung cancerNature (London), 2018-01, Vol.553 (7689), p.446-454 [Peer Reviewed Journal]COPYRIGHT 2018 Nature Publishing Group ;COPYRIGHT 2018 Nature Publishing Group ;Copyright Nature Publishing Group Jan 25, 2018 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/nature25183 ;PMID: 29364287Full text available |
|
8 |
Material Type: Article
|
Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screeningOncotarget, 2015-10, Vol.6 (32), p.32868-32877Copyright: © 2015 Sestini et al. 2015 ;ISSN: 1949-2553 ;EISSN: 1949-2553 ;DOI: 10.18632/oncotarget.5210 ;PMID: 26451608Full text available |
|
9 |
Material Type: Article
|
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung CancerJournal of clinical oncology, 2021-03, Vol.39 (7), p.723-733 [Peer Reviewed Journal]2021 by American Society of Clinical Oncology 2021 American Society of Clinical Oncology ;ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/jco.20.01605 ;PMID: 33449799Full text available |
|
10 |
Material Type: Article
|
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung CancerThe New England journal of medicine, 2020-10, Vol.383 (18), p.1711-1723 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2027071 ;PMID: 32955177Full text available |
|
11 |
Material Type: Article
|
miR-Test: a blood test for lung cancer early detectionJNCI : Journal of the National Cancer Institute, 2015-06, Vol.107 (6), p.djv063-djv063 [Peer Reviewed Journal]The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. ;Copyright Oxford Publishing Limited(England) Jun 2015 ;ISSN: 0027-8874 ;EISSN: 1460-2105 ;DOI: 10.1093/jnci/djv063 ;PMID: 25794889 ;CODEN: JNCIEQFull text available |
|
12 |
Material Type: Article
|
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialThe lancet oncology, 2014-02, Vol.15 (2), p.213-222 [Peer Reviewed Journal]Elsevier Ltd ;2014 Elsevier Ltd ;Copyright © 2014 Elsevier Ltd. All rights reserved. ;Copyright Elsevier Limited Feb 2014 ;ISSN: 1470-2045 ;EISSN: 1474-5488 ;DOI: 10.1016/S1470-2045(13)70604-1 ;PMID: 24439929 ;CODEN: LANCAOFull text available |
|
13 |
Material Type: Article
|
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerThe New England journal of medicine, 2019-11, Vol.381 (21), p.2020-2031 [Peer Reviewed Journal]Copyright © 2019 Massachusetts Medical Society. All rights reserved. ;Copyright © 2019 Massachusetts Medical Society. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1910231 ;PMID: 31562796Full text available |
|
14 |
Material Type: Article
|
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLCThe New England journal of medicine, 2020-10, Vol.383 (14), p.1328-1339 [Peer Reviewed Journal]Copyright © 2020 Massachusetts Medical Society. All rights reserved. ;Copyright © 2020 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1917346 ;PMID: 32997907Full text available |
|
15 |
Material Type: Article
|
Integrating genomic features for non-invasive early lung cancer detectionNature (London), 2020-04, Vol.580 (7802), p.245-251 [Peer Reviewed Journal]COPYRIGHT 2020 Nature Publishing Group ;COPYRIGHT 2020 Nature Publishing Group ;Copyright Nature Publishing Group Apr 9, 2020 ;ISSN: 0028-0836 ;EISSN: 1476-4687 ;DOI: 10.1038/s41586-020-2140-0 ;PMID: 32269342Full text available |
|
16 |
Material Type: Article
|
Allele-Specific HLA Loss and Immune Escape in Lung Cancer EvolutionCell, 2017-11, Vol.171 (6), p.1259-1271.e11 [Peer Reviewed Journal]2017 The Francis Crick Institute ;Copyright © 2017 The Francis Crick Institute. Published by Elsevier Inc. All rights reserved. ;2017 The Francis Crick Institute 2017 ;ISSN: 0092-8674 ;EISSN: 1097-4172 ;DOI: 10.1016/j.cell.2017.10.001 ;PMID: 29107330Full text available |
|
17 |
Material Type: Article
|
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCThe New England journal of medicine, 2018-12, Vol.379 (24), p.2342-2350 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 0028-4793 ;ISSN: 1533-4406 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1809697 ;PMID: 30280658Full text available |
|
18 |
Material Type: Article
|
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerThe New England journal of medicine, 2018-05, Vol.378 (22), p.2078-2092 [Peer Reviewed Journal]Copyright © 2018 Massachusetts Medical Society. All rights reserved. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa1801005 ;PMID: 29658856Full text available |
|
19 |
Material Type: Article
|
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterJournal of clinical oncology, 2019-03, Vol.37 (7), p.537-546 [Peer Reviewed Journal]ISSN: 0732-183X ;EISSN: 1527-7755 ;DOI: 10.1200/JCO.18.00149 ;PMID: 30620668Full text available |
|
20 |
Material Type: Article
|
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLCThe New England journal of medicine, 2023-07, Vol.389 (2), p.137-147 [Peer Reviewed Journal]Copyright © 2023 Massachusetts Medical Society. All rights reserved. ;Copyright © 2023 Massachusetts Medical Society. ;ISSN: 0028-4793 ;EISSN: 1533-4406 ;DOI: 10.1056/NEJMoa2304594 ;PMID: 37272535Full text available |